Monoclonal antibody recognizing human papillomavirus (HPV) L2 protein and method for measuring HPV-neutralizing antibody titer using the same
The present invention relates to the development of a monoclonal antibody which has binding activity to many high-risk types of HPV, etc. The present invention also provides a simple and high-throughput method for measuring cross-neutralizing antibody titers, which is used for assay of cross-neutralizing antibody against HPV in serum samples from subjects, etc. The method of the present invention for measuring cross-neutralizing antibody titers comprises the steps of: preparing a monoclonal antibody against a peptide having a specific amino acid sequence common to high-risk types of HPV; and assaying cross-neutralizing antibody using this monoclonal antibody.
1. A monoclonal antibody which recognizes a common epitope in human papillomavirus L2 protein, said epitope consisting of SEQ ID NO: 2 or SEQ ID NO: 24, wherein said antibody comprises the amino acid sequences shown in SEQ ID NO: 11 (CDRH1), SEQ ID NO: 12 (CDRH2), SEQ ID NO: 13 (CDRH3), SEQ ID NO: 14 (CDRL1), SEQ ID NO: 15 (CDRL2) and SEQ ID NO: 16 (CDRL3).
2. A monoclonal antibody which recognizes a common epitope in human papillomavirus L2 protein, said epitope consisting of SEQ ID NO: 3 or SEQ ID NO: 25, wherein said antibody comprises the amino acid sequences shown in SEQ ID NO: 17 (CDRH1), SEQ ID NO: 18 (CDRH2), SEQ ID NO: 19 (CDRH3), SEQ ID NO: 20 (CDRL1), SEQ ID NO: 21 (CDRL2) and SEQ ID NO: 22 (CDRL3).
3. The monoclonal antibody according to claim 1 , whose heavy chain variable region is the amino acid sequence shown in SEQ ID NO: 7 and whose light chain variable region is the amino acid sequence shown in SEQ ID NO: 8.
4. The monoclonal antibody according to claim 2 , whose heavy chain variable region is the amino acid sequence shown in SEQ ID NO: 9 and whose light chain variable region is the amino acid sequence shown in SEQ ID NO: 10.
5. The monoclonal antibody according to claim 3 , which recognizes human papillomavirus L2 protein and is produced by a hybridoma cell line of accession No. FERM BP-11304.
6. The monoclonal antibody according to claim 4 , which recognizes human papillomavirus L2 protein and is produced by a hybridoma cell line of accession No. FERM BP-11305.
7. A kit which comprises (a) an HPV antigen immobilized on a solid support, (b) the monoclonal antibody according to claim 1 or claim 2 , and (c) a labeled secondary antibody recognizing the monoclonal antibody of (b).
8. A diagnostic reagent for HPV infection, which comprises the monoclonal antibody according to claim 1 or claim 2 .
9. A cell line, which produces the monoclonal antibody according to claim 1 or claim 2 .
10. The cell line according to claim 9 , whose accession No. is FERM BP-11304 or FERM BP-11305.
11. A pharmaceutical preparation, which comprises the monoclonal antibody according to claim 1 or claim 2 .
12. A therapeutic agent for HPV, which comprises the monoclonal antibody according to claim 1 or claim 2 .